throbber
United States Patent
`Ding et al.
`
`[19]
`
`111111111111111111111111111111111111111111111111111111111111111111111111111
`US0054 7 4979 A
`Patent Number:
`Date of Patent:
`
`5,474,979
`Dec. 12, 1995
`
`[11]
`
`[45]
`
`[54] NONIRRITATING EMULSIONS FOR
`SENSITIVE TISSUE
`
`[75]
`
`Inventors: Shulin Ding; Walter L. Tien, both of
`Irvine; Orest Olejnik, Trabuco Canyon,
`all of Calif.
`
`[73] Assignee: Allergan, Inc., Irvine, Calif.
`
`[21] Appl. No.: 243,279
`
`[22] Filed:
`
`May 17, 1994
`
`Int. Cl.6
`........................... A61K 38/13; A61K 47/34
`[51]
`[52] U.S. Cl . ............................ 514111; 514/785; 514/786;
`5141912; 514/941; 514/943; 514/975
`[58] Field of Search ..................................... 530/317, 321;
`514/9, 11, 785, 786, 912, 913, 914, 915,
`941, 943, 975, 178, 179, 180, 181, 420,
`784; A61K 91107, 47114
`
`[56]
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,839,342
`4,990,337
`4,996,193
`5,051,402
`5,364,632
`
`6/1989 Kaswan ..................................... 514111
`211991 Kurihara et al ......................... 424/427
`2/1991 Hewitt et al .............................. 514111
`9/1991 Kurihara et al. ......... ........... ...... 514/11
`1111994 Benita et al ............................ 514/943
`
`Primary Examiner-Jeffrey E. Russel
`Attorney, Agent, or Firm-Walter A. Hackler
`
`[57]
`
`ABSTRACT
`
`A pharmaceutical composition is disclosed in the form of a
`nonirritating emulsion which
`includes at
`least one
`cyclosporin in admixture with a higher fatty acid glyceride
`and polysorbate 80. More particularly, the cyclosporin may
`be cyclosporin A and the higher fatty acid glyceride may be
`castor oil. Composition has been found to be of a high
`comfort level and low irritation potential suitable for deliv(cid:173)
`ery of medications to sensitive areas such as ocular tissues.
`In addition, the composition has stability for up to nine
`months without crystallization of cyclosporin.
`
`4,347,238
`
`8/1982 Hollingsbee ............................ 5141179
`
`8 Claims, No Drawings
`
`APOTEX 1003, pg. 1
`
`

`

`1
`NONIRRITATING EMULSIONS FOR
`SENSITIVE TISSUE
`
`5,474,979
`
`50
`
`The present invention generally relates to novel pharma(cid:173)
`ceutical compositions incorporating chemicals which are 5
`poorly soluble in water and is more particularly related to a
`novel ophthalmic emulsion including cyclosporin in admix(cid:173)
`ture with castor oil and polysorbate 80 with high comfort
`level and low irritation potential.
`Cyclosporins are a group of nonpolar cyclic oligopep(cid:173)
`tides with known immunosuppressant activity. In addition,
`as set forth in U.S. Pat. No. 4,839,342, cyclosporin (some(cid:173)
`times referred to in the literature as "cyclosporine") has been
`found as effective in treating immune medicated keratocon(cid:173)
`junctivitis sicca (KCS or dry eye disease) in a patient
`suffering therefrom.
`As hereinabove noted, cyclosporin comprises a group of
`cyclic oligopeptides and the major component thereof is
`cyclosporin A (C62H111N 110n) which has been identified
`along with several other minor metabolites, cyclosporin B
`through I. In addition, a number of synthetic analogs have
`been prepared.
`In general, commercially available cyclosporins may
`contain a mixture of several individual cyclosporins which
`all share a cyclic peptide structure consisting of eleven
`amino acid residues with a total molecular weight of about
`1,200, but with different substituents or configurations of
`some of the amino acids.
`It should be appreciated that reference to the term
`"cyclosporin" or "cyclosporins" is used throughout the
`present specification in order to designate the cyclosporin
`component in the composition of the present invention.
`However, this specific reference is intended to include
`any individual member of the cyclosporin group as well as
`admixtures of two or more individual cyclosporins, whether
`natural or synthetic.
`The activity of cyclosporins, as hereinabove noted, is as
`an immunosuppressant and in the enhancement or restoring
`of lacrimal gland tearing.
`Unfortunately, the solubility of cyclosporin in water is
`extremely low and as elaborated in U.S. Pat. No. 5,051,402,
`it has been considered not merely difficult but practically
`impossible to prepare a pharmaceutical composition con(cid:173)
`taining cyclosporin dissolved in an aqueous medium.
`As reported, the solubility of cyclosporin in water is
`between about 20 !lg/ml to 30 !lg/ml for cyclosporin A.
`Hence, heretofore prepared formulations
`incorporating
`cyclosporin have been prepared as oily solutions containing
`ethanol. However, these preparations limit the bioavailabil(cid:173)
`ity to oral preparations and this is believed to be due to the
`separation of cyclosporin as a solid immediately after it
`comes into contact with water, such as in the mouth or eye
`of a patient.
`In the case of injectable preparations of cyclosporin, they
`first must be diluted with physiological saline before intra(cid:173)
`venous administration but this is likely to result in the
`precipitation of cyclosporin and therefore may be considered
`undesirable for intravenous administration.
`Surface active agents such as polyoxyethylated castor oil
`have been utilized as solubilizers to inject preparations in
`order to prevent cyclosporin from separating. However, this
`also may give rise to safety problems (see U.S. Pat. No.
`5,051,402).
`The practical usefulness of cyclosporin would be greatly
`enhanced if administration thereof could be effective; for 65
`example, cyclosporin's effectiveness in the treatment of
`ocular symptoms of Behcet's Syndrome. However, if it is
`
`2
`administered orally for the treatment of these symptoms, the
`accompanying side effects due to systemic circulation may
`cause adverse reactions such as hypertrichosis or renal
`dysfunction.
`On the other hand, if oily preparations containing
`cyclosporin are applied directly to the eyes, irritation or a
`clouding of visual field may result. This plus the difficulty in
`formulating cyclosporin limits its use in formulations that
`would be useful during keratoplasty as well in the treatment
`10 of herpetic keratitis and spring catarrh.
`Heretofore, as for example in U.S. Pat. No. 5,051,402,
`attempts have been made to dissolve sufficient cyclosporin
`in an aqueous solvent system so as to reach an effective
`concentration for treatment. Importantly, this solvent system
`15 does not contain any surface active agent such as polyoxy(cid:173)
`ethy lated castor oil.
`Conceptually, the purpose of dissolving the cyclosporin
`in an aqueous solvent system is to enable contact with body
`fluids which would merely constitute dilution of the aqueous
`20 solvent system which hopefully would eliminate the imme(cid:173)
`diate precipitation of cyclosporin when contacted with the
`water content of the body fluids.
`For direct use in the eye, cyclosporin has been formu(cid:173)
`lated with a number of pharmaceutically acceptable excipi-
`25 ents, for example, animal oil, vegetable oil, an appropriate
`organic or aqueous solvent, an artificial tear solution, a
`natural or synthetic polymer or an appropriate membrane.
`Specific examples of these pharmaceutically acceptable
`excipients, which may be used solely or in combination, are
`30 olive oil, arachis oil, castor oil, mineral oil, petroleum jelly,
`dimethyl sulfoxide, chremophor, liposomes, or liposome(cid:173)
`like products or a silicone fluid, among others.
`In summary, a great deal of effort has been expended in
`order to prepare a pharmaceutical composition containing
`35 cyclosporin dissolved in an aqueous medium or cyclosporin
`prepared as an oily solution. However, successful formula(cid:173)
`tions have yet to be accomplished as evidenced by the lack
`of commercial products.
`it has been reported that
`As hereinabove noted,
`40 cyclosporin has demonstrated some solubility in oily prepa(cid:173)
`rations containing higher fatty acid glycerides such as olive
`oil, peanut oil, and/or castor oil. These formulations fre(cid:173)
`quently produce an unpleasant sensation when applied to the
`eye because of stimulation or the viscousness which is
`45 characteristic of these oils.
`Another drawback of these formulations is that they
`contain a high concentration of oils, and oils exacerbate the
`symptoms of certain ocular surface diseases such as dry
`eyes, indicated by cyclosporin. Therefore, these oily formu-
`lations may not be clinically acceptable. Additionally, these
`formulations often suffer from physical instability due to
`cyclosporin' s propensity to undergo conformational change
`and crystallize out. The crystallization problem has been
`noticed in formulations containing com oil or medium chain
`triglycerides. Lastly, these formulations often have a low
`thermodynamic
`activity
`(degree of
`saturation) of
`cyclosporin which leads to a poorer drug bioavailability.
`It may be possible to minimize the problems related to
`unpleasant sensation and syndrome exacerbation by reduc-
`ing the oil content and dispersing the oil phase in water into
`an emulsion. However, it is not an easy task to formulate an
`ophthalmic emulsion because one indispensable class of
`ingredients in an emulsion system is emulsifiers, and the
`majority of emulsifiers is highly irritating to the eyes.
`The present invention is directed to an emulsion system
`which utilizes higher fatty acid glycerides but in combina(cid:173)
`tion with polysorbate 80 which results in an emulsion with
`
`60
`
`55
`
`APOTEX 1003, pg. 2
`
`

`

`5,474,979
`
`3
`a high comfort level and low irritation potential suitable for
`delivery of medications to sensitive areas such as ocular
`tissues.
`
`SUMMARY OF THE INVENTION
`
`4
`Pemulen® is a registered trademark of B. F. Goodrich for
`polymeric emulsifiers and commercially available from B. F.
`Goodrich Company, Specialty Polymers & Chemicals Divi(cid:173)
`sion, Cleveland, Ohio. Pemulens are Acrylates/Cl0-30
`5 Alkyl Acrylate Cross-Polymers. They are high molecular
`weight co-polymers of acrylic acid and a long chain alkyl
`methacrylate cross-linked with allyl ethers of pentaerythri(cid:173)
`tol. They contain not less than 52.0 percent and not more
`than 62.0 percent of carboxylic acid groups. The viscosity of
`a neutralized 1.0 percent aqueous dispersion is between
`9,500 and 26,500 centipoises.
`In addition, the tonicity of the emulsions can be further
`adjusted using glycerine, mannitol, or sorbitol if desired.
`The pH of the emulsions can be adjusted in a conventional
`manner using sodium hydroxide to a near physiological pH
`level and while buffering agents are not required, suitable
`buffers may include phosphates, citrates, acetates and
`borates.
`While the preferable medications in accordance with the
`present invention include cyclosporin, other chemicals
`which are poorly soluble in water such as indomethacin and
`steroids such as androgens, prednisolone, prednisolone
`acetate, fiuorometholone, and dexamethasones, may be
`25 emulsified with castor oil and polysorbate 80 resulting in a
`composition with similar low irritation potential.
`The invention is further illustrated by the following
`examples with all parts and percentages expressed by
`weight. The cyclosporin used in the examples was supplied
`30 by Sandoz.
`
`20
`
`10
`
`In accordance with the present invention, a nonirritating
`pharmaceutical composition with high comfort level and
`low irritation potential suitable for delivery to sensitive areas
`such as ocular tissues comprises cyclosporin in admixture
`with an emulsifying amount of a higher fatty acid glycerol
`and polysorbate 80. More particularly, the composition may
`comprise cyclosporin A and the higher fatty acid glyceride
`may comprise castor oil.
`Preferably, the weight ratio of the castor oil to the 15
`polysorbate 80 is between about 0.3 to about 30 and a weight
`ratio of the cyclosporin to castor oil is below 0.16. More
`preferably, the weight ratio of castor oil to polysorbate 80 is
`between 0.5 and 12.5, and the weight ratio of cyclosporin to
`castor oil is between 0.12 and 0.02.
`When cyclosporin is dissolved in the oil phase in accor(cid:173)
`dance with the present invention, the emulsion is found to be
`physically stable upon long term storage. No crystallization
`of cyclosporin was noticed after nine months at room
`temperature. Moreover, the cyclosporin emulsion is formu(cid:173)
`lated in such a way that the drug has reasonably high
`thermodynamic activity, yet without the crystallization prob(cid:173)
`lem.
`
`DETAILED DESCRIPTION
`
`As hereinabove noted, cyclosporin is available as a mix(cid:173)
`ture in which the principal ingredient is cyclosporin A with
`significant, but smaller, quantities of other cyclosporins such
`as cyclosporin B through I. However, as also hereinabove 35
`noted, the present invention may be applied to either a pure
`cyclosporin or to a mixture of individual cyclosporins.
`The discovery on which the present invention is founded
`relates to a combination of a higher fatty acid glyceride and
`an emulsifier and dispersing agent, polysorbate 80. The 40
`selection of these components could not have been antici(cid:173)
`pated on the basis of conventional thinking.
`For example, although it is well-known that cyclosporin
`may be used in combination with castor oil, this combination
`is irritating to sensitive tissues such as the eye. Thus, 45
`conventional teaching in the art is away from a formulation
`which utilizes a higher fatty acid glyceride, such as castor
`oil, and cyclosporin.
`Stated another way, there is no way of deducing that the
`use of an emulsifier and dispersing agent such as polysorbate
`80 will reduce the irritation potential of an emulsion utiliz(cid:173)
`ing castor oil. There are no examples of polysorbate in
`combination with castor oil which, when admixed to
`cyclosporin, produces an emulsion with a high comfort level
`and low irritation potential suitable for the delivery of
`medication to sensitive areas such as ocular tissues.
`The present invention achieves a stable solution state of
`cyclosporin. This stable solution state is another important
`performance characteristic differentiating the present inven- 60
`tion from the conventional oil systems. Cyclosporin is
`notorious for its tendency to precipitate out in conventional
`oil systems in which it is fully dissolved initially.
`In accordance with the present invention, the emulsions
`can be further stabilized using a polyelectrolyte, or poly- 65
`electrolytes if more than one, from the family of cross-linked
`polyacrylates, such as carbomers and Pemulen®.
`
`55
`
`50
`
`Example I
`
`A
`
`B
`
`0.40%
`5.00%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`0.20%
`5.00%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`c
`
`0.20%
`2.50%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`D
`
`E
`
`0.10%
`1.25%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`0.05%
`0.625%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`Example 2
`
`A
`
`B
`
`5.00%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`2.50%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`Example 3
`
`c
`
`1.25%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`D
`
`0.625%
`1.00%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`A
`
`2.50%
`0.75%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`A
`
`5.00%
`
`Example 4
`
`Cyclosporin A
`Castor oil
`Polysorbate 80
`Pemulen®
`Glycerine
`NaOH
`Purified water
`pH
`
`Castor oil
`Polysorbate 80
`Pemulen®
`Glycerine
`NaOH
`Purified water
`pH
`
`Castor oil
`Polysorbate 80
`Carbomer 1382
`Glycerine
`NaOH
`Purified water
`pH
`
`Castor oil
`
`APOTEX 1003, pg. 3
`
`

`

`5,474,979
`
`5
`
`-continued
`
`0.75%
`0.05%
`2.20%
`qs
`qs
`7.2-7.6
`
`Polysorbate 80
`Carbomer 981
`Glycerin
`NaOH
`Purified water
`pH
`
`The formulations set forth in Examples 1-4 were made
`for treatment of keratoconjunctivitis sicca (dry eye) syn(cid:173)
`drome with Examples 2, 3 and 4 without the active ingre(cid:173)
`dient cyclosporin utilized to determine the toxicity of the
`emulsified components.
`The formulations in Examples 1-4 were applied to rabbit
`eyes eight times a day for seven days and were found to
`cause only slight to mild discomfort and slight hyperemia in
`the rabbit eyes. Slit lamp examination revealed no changes
`in the surface tissue. In addition, the cyclosporin containing
`castor oil emulsion, as hereinabove set forth in Examples
`lA-lD, was also tested for ocular bioavailability in rabbits;
`and the therapeutic level of cyclosporin was found in the
`tissues of interest after dosage. This substantiates that
`cyclosporin in an ophthalmic delivery system is useful for
`treating dry eye as set forth in U.S. Pat. No. 4,839,342.
`In addition, no difference in toxicity was found between
`formulations with cyclosporin (Examples lA-lD) and for(cid:173)
`mulations without cyclosporin (Examples 2-4).
`The formulations set forth in Examples 1-4 were found to
`be physically stable upon long term storage. With regard to
`formulations 1A-1D, no crystallization of cyclosporin was
`noticed after nine months at room temperature.
`Further, other higher fatty acid glycerides such as olive
`oil, peanut oil and the like may also be utilized with the
`polysorbate 80 with similar results regarding biotoxicity.
`Although there has been hereinabove described a particu(cid:173)
`lar pharmaceutical composition in the form of a nonirritating
`emulsion for the purpose of illustrating the manner in which
`the invention may be used to advantage, it should be
`appreciated that the invention is not limited thereto. Accord(cid:173)
`ingly, any and all modifications, variations, or equivalent
`arrangements, which may occur to those skilled in the art,
`should be considered to be within the scope of the present
`
`10
`
`20
`
`6
`invention as defined in the appended claims.
`What is claimed is:
`1. A pharmaceutical composition comprising a nonirritat(cid:173)
`ing emulsion of at least one cyclosporin in admixture with
`5 a higher fatty acid glyceride, polysorbate 80 and an emulsion
`stabilizing amount of Pemulen in water suitable for topical
`application to ocular tissue.
`2. The pharmaceutical composition according to claim 1
`wherein the cyclosporin comprises cyclosporin A.
`3. The pharmaceutical composition according to claim 2
`wherein the weight ratio of the higher fatty acid glyceride to
`the polysorbate 80 is between about 0.3 and about 30.
`4. The pharmaceutical composition according to claim 3
`wherein the higher fatty acid glyceride comprises castor oil
`15 and the weight ratio of cyclosporin to castor oil is below
`about 0.16.
`5. The composition according to claim 1 wherein the
`higher fatty acid glyceride and polysorbate 80 are present in
`amounts sufficient to prevent crystallization of cyclosporin
`for a period of up to about nine months.
`6. A pharmaceutical emulsion comprising of cyclosporin
`A, castor oil, Pemulen, glycerine, polysorbate 80 water in
`amounts sufficient to prevent crystallization of cyclosporin A
`for a period of up to about nine months, said pharmaceutical
`25 emulsion being suitable for topical application to ocular
`tissue.
`7. The pharmaceutical emulsion according to claim 6
`wherein the cyclosporin A is present in an amount of
`between about 0.05 to and about 0.40%, by weight, the
`30 castor oil is present in an amount of between about 0.625%,
`by weight, and about 5.0%, by weight, the polysorbate 80 is
`present in an amount of about 1.0%, by weight, the Pemulen
`is present in an amount of about 0.05%, by weight, and the
`glycerine is present in an amount of about 2.2%, by weight.
`8. A pharmaceutical emulsion consisting of between about
`0.05% and about 0.40%, by weight, cyclosporin A, between
`about 0.625% and about 5.0%, by weight, castor oil, about
`1.0%, by weight, polysorbate 80, about 0.05%, by weight,
`Pemulen and about 2.2%, by weight, glycerine in water with
`40 a pH of between about 7.2 and 7.6 suitable for topical
`application to ocular tissue.
`
`35
`
`* * * * *
`
`APOTEX 1003, pg. 4
`
`

`

`1111111111111111111111111111111111111111111111111111111111111
`US005474979Cl
`c12) EX PARTE REEXAMINATION CERTIFICATE (9030th)
`United States Patent
`US 5,474,979 Cl
`c1o) Number:
`Ding et al.
`(45) Certificate Issued: May 29, 2012
`
`111111
`
`(54) NONIRRITATING EMULSIONS FOR
`SENSITIVE TISSUE
`
`(75)
`
`Inventors: Shulin Ding, Irvine, CA (US); Walter
`L. Tien, Irvine, CA (US); Orest Olejnik,
`Trabuco Canyon, CA (US)
`
`(73) Assignee: Allergan, Inc., Irvine, CA (US)
`
`Reexamination Request:
`No. 90/009,944, Aug. 27, 2011
`
`Reexamination Certificate for:
`5,474,979
`Patent No.:
`Dec. 12, 1995
`Issued:
`08/243,279
`Appl. No.:
`May 17, 1994
`Filed:
`
`(51)
`
`Int. Cl.
`A61K 9100
`A61K 91107
`A61K 38100
`A61K 38112
`A61K 38113
`A61K 47110
`A61K 47114
`A61K 47132
`A61K 47134
`A61P 27102
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`(52) U.S. Cl. ...................... 514/20.5; 514/20.8; 514/785;
`514/786; 514/912; 514/941; 514/943; 514/975
`(58) Field of Classification Search ........................ None
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`To view the complete listing of prior art documents cited
`during the proceeding for Reexamination Control Number
`90/009,944, please refer to the USPTO's public Patent
`Application Information Retrieval (PAIR) system under the
`Display References tab.
`
`Primary Examiner-Gary Kunz
`
`(57)
`
`ABSTRACT
`
`A pharmaceutical composition is disclosed in the form of a
`nonirritating emulsion which includes at least one
`cyclosporin in admixture with a higher fatty acid glyceride
`and polysorbate 80. More particularly, the cyclosporin may
`be cyclosporin A and the higher fatty acid glyceride may be
`castor oil. Composition has been found to be of a high com(cid:173)
`fort level and low irritation potential suitable for delivery of
`medications to sensitive areas such as ocular tissues. In
`addition, the composition has stability for up to nine months
`without crystallization of cyclosporin.
`
`APOTEX 1003, pg. 5
`
`

`

`US 5,474,979 Cl
`
`1
`EX PARTE
`REEXAMINATION CERTIFICATE
`ISSUED UNDER 35 U.S. C. 307
`
`NO AMENDMENTS HAVE BEEN MADE TO
`THE PATENT
`
`2
`AS A RESULT OF REEXAMINATION, IT HAS BEEN
`DETERMINED THAT:
`
`The patentability of claims 1-8 is confirmed.
`
`* * * * *
`
`APOTEX 1003, pg. 6
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket